Cargando…
Tumor Recurrence in a Glioblastoma Patient after Discontinuation of Prolonged Temozolomide Treatment
There is no consensus regarding the duration of temozolomide (TMZ) treatment for glioblastoma multiforme (GBM). We report a 53-year-old woman who had a left frontal GBM. The tumor showed good response to TMZ treatment, which was discontinued after 5.5 years with recurrence of tumor at the posterior...
Autores principales: | Tseng, Wei-Lung, Hsu, Hsu-Hsien, Chen, Yun, Tseng, Sheng-Hong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652107/ https://www.ncbi.nlm.nih.gov/pubmed/29114295 http://dx.doi.org/10.4103/ajns.AJNS_39_15 |
Ejemplares similares
-
Apatinib Plus Temozolomide: An Effective Salvage Treatment for Recurrent Glioblastoma
por: Ge, Jingjing, et al.
Publicado: (2021) -
Continuous Low-Dose Temozolomide Chemotherapy and Microvessel Density in Recurrent Glioblastoma
por: Woo, Jong-Yun, et al.
Publicado: (2015) -
Focused Ultrasound-Induced Blood–Brain Barrier Opening to Enhance Temozolomide Delivery for Glioblastoma Treatment: A Preclinical Study
por: Wei, Kuo-Chen, et al.
Publicado: (2013) -
Long-term remission in an aggressive Crooke cell adenoma of the pituitary, 18 months after discontinuation of treatment with temozolomide
por: Asimakopoulou, Athina, et al.
Publicado: (2014) -
Obstacles to Glioblastoma Treatment Two Decades after Temozolomide
por: Cruz, João Victor Roza, et al.
Publicado: (2022)